| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $952,105 | +31,558 | +42% | $30.17 | 106,556 | 22 Feb 2023 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $191,812 | -4,526 | -4.2% | $42.38 | 102,030 | 22 Feb 2023 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | $839,521 | -19,211 | -19% | $43.70 | 82,819 | 22 Feb 2023 | Direct | F3, F4 |
| holding | PFE | Common Stock | 5,973 | 22 Feb 2023 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -31,558 | -100% | $0.000000* | 0 | 22 Feb 2023 | Common Stock | 31,558 | $30.17 | Direct | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +24,797 | $0.000000 | 24,797 | 23 Feb 2023 | Common Stock | 24,797 | $42.30 | Direct | F5 | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +21,581 | $0.000000 | 21,581 | 23 Feb 2023 | Common Stock | 21,581 | $42.30 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| F5 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| F6 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |